Fig 1: Represented the S100A12 concentration by mean ± SD in the different groups in three boxes. According to this chart, the concentration of S100A12 decreased significantly in two untreated RRMS and high-risk groups compared to the healthy control group (P < 0.05).
Fig 2: The plasma concentration of S100A12 showed a positive correlated with the age in the untreated RRMS group (Spearman; r = 0.498 and P = 0.002) (A), and in the high-risk (Spearman; r = 0.410 and P = 0.038) (B). Apo-A1 plasma level also revealed a positive correlated to the age in both untreated RRMS and in the high-risk groups (Spearman; r = 0.401 and P = 0.017) (C), (Spearman; r = 0.614 and P = 0.001) (D) respectively.
Fig 3: In the new cases untreated RRMS patients, S100A12 level was declined in the female more than in males (Mann–Whitney; p = 0.03) (A). S100A12 level was also reduced in the females than in the males in the high-risk group (Mann–Whitney; P = 0.029) (B). Apo-A1 levels were decreased in the females than males in both untreated RRMS patients and high-risk groups respectively (Mann–Whitney; P = 0.011) (C) (Mann–Whitney; P = 0.001) (D).
Supplier Page from BosterBio for Human S100A12/En Rage ELISA Kit PicoKine®